Our science & medical news
RSS feedResearchers from the Institute at the 15th MGFA International Conference
Institute researchers at the 15th International MGFA ConferenceInstitute experts presented their work at the 15th International MGFA Conference on myasthenia gravis and associated disorders, held from 13 May to 15 May 2025 in The Hague, Netherlands. Organised by the Myasthenia Gravis Foundation of America (MGFA), this conference brings together neuromuscular researchers and healthcare professionals to … [Read more]
A new murine model of myasthenia gravis that is more effective and better suited to animal welfare
The Myasthenia gravis, etiology, pathophysiology & therapeutical approaches team, led by Rozen Le Panse at the Institute of Myology’s Myology Research Centre, has developed a new experimental murine model of myasthenia gravis (N-EAMG) that is at least as effective as the classic experimental model (C-EAMG) and offers several advantages. N-EAMG: is better suited to animal … [Read more]
Identification of effective, non-invasive MRI markers in LGMD R9
French researchers from the Institute of Myology, Genethon and Atamyo, in collaboration with Dutch researchers, have studied several quantitative MRI parameters in order to identify sensitive and non-invasive biomarkers for assessing the progression of LGMD-R9 and evaluating the efficacy of new therapies. Carried out in 18 persons with LGMD-R9 and 13 controls, this study shows … [Read more]
The benefit of reusing data from placebo groups in inclusion myositis
American researchers associated with the Institute of Myology Research Centre have compiled and re-analysed the data accumulated in the placebo arms of several clinical trials in inclusion myositis (IMM) : 11 therapeutic trials were selected, they involved 257 participants who had received only a placebo, the main endpoints were changes in muscle strength and, in … [Read more]
Long-term data on the evolution of patients with congenital myopathy
The Centre de référence des maladies neuromusculaires of the Institute of Myology conducted a single-centre observational study of 142 adult patients with congenital myopathy followed up between 1996 and 2019, for a median duration of 8 years. Congenital myopathies with cores linked to the RYR1 gene and centronuclear myopathies linked to the DNM2 gene were … [Read more]
Researchers from the Institute’s imaging laboratory at the SFRMBM conference
Experts from the Institute’s NMR Laboratory – Spectroscopy Laboratory presented their work at the 7th scientific congress of the Société Française de Résonance Magnétique en Biologie et Médecine (SFRMBM), held in Saint-Malo, France, from 24 to 26 March 2025. Oral communications Monday 24 March • Course – « MR Fingerprinting: Practical Guide » – Benjamin … [Read more]
Two molecules with therapeutic potential identified in LGMD R2
A collaboration involving I-Stem, Genethon and the Institute of Myology carried out a high-throughput screening of 2,239 drugs already approved for other diseases and other bioactive compounds on immortalised myoblast models of limb-girdle muscular dystrophy type R2 (LGMD R2) carrying the L1341P missense mutation in the DYSF gene or in muscle fibres from dysferlin-deficient mice: … [Read more]
Checkpoint inhibitors can induce myositis, but more rarely myasthenia gravis
A French study involving several researchers and clinicians from the Institute of Myology has retrospectively demonstrated the toxic effects of checkpoint inhibitors (ICIs), innovative products widely used in oncology: previous studies had reported cases of induced myasthenia or, more frequently, induced myositis, Using the AP-HP data warehouse, 620 records of patients treated in this way … [Read more]
FSHD combined with genuine myositis: an intriguing association
A French study involving clinicians from the Institute of Myology reports several new and disturbing cases of patients with two co-existing neuromuscular pathologies: firstly, facioscapulohumeral muscular dystrophy (FSHD), proven by molecular biology, and secondly, myositis authenticated by the presence of specific autoantibodies, of the 5 cases of this type identified in the myositis database of … [Read more]
DMD: an effective gene therapy in a severe mouse model of the disease leads to cardiac inflammation
Duchenne muscular dystrophy, a severe and progressive hereditary muscular dystrophy, is caused by mutations in the DMD gene leading to the loss of a protein essential for muscle function, dystrophin. There is currently no effective treatment, but gene therapy trials using micro-dystrophins have been underway for several years. These strategies, targeting both skeletal and cardiac muscle, are applicable to all … [Read more]
